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Significance of this study
What is already known about this subject?
 ► Choosing therapies for type 2 diabetes that are both 
effective and cost- effective is vital as healthcare 
systems worldwide aim to maximize health of the 
population, and the WHO recommends the use of 
cost- effectiveness analysis to ensure that interven-
tions funded by a healthcare system represent good 
value for money. The cost- effectiveness of once- 
weekly semaglutide, a novel glucagon- like peptide-1 
receptor agonist, has been assessed in a number of 
countries, but numerous factors may influence the 
cost- effectiveness of interventions in different set-
tings. The aim of the present analysis was to assess 
the cost- effectiveness of once- weekly semaglutide 
from a societal perspective in the Netherlands.
What are the new findings?
 ► Projections of outcomes over patient lifetimes sug-
gest that once- weekly semaglutide 0.5 mg and 1 mg 
are likely to improve clinical outcomes for patients 
with type 2 diabetes compared with insulin glargine 
U100 and dulaglutide. Compared with insulin 
glargine U100, improvements in clinical outcomes 
came at an increased cost, but once- weekly sema-
glutide was considered cost- effective, even at the 
lowest willingness- to- pay threshold identified in the 
Netherlands. Improvements came at a reduced cost 
from a societal perspective versus dulaglutide, and 
therefore once- weekly semaglutide was considered 
dominant.
How might these results change the focus of 
research or clinical practice?
 ► Use of once- weekly semaglutide for treatment of 
patients with type 2 diabetes is likely to be a good 
use of healthcare resources in the Netherlands.
AbStrAct
Objective Choosing therapies for type 2 diabetes 
that are both effective and cost- effective is vital as 
healthcare systems worldwide aim to maximize health 
of the population. The present analysis assessed the 
cost- effectiveness of once- weekly semaglutide (a novel 
glucagon- like peptide-1 (GLP-1) receptor agonist) versus 
insulin glargine U100 (the most commonly used basal 
insulin) and versus dulaglutide (an alternative once- weekly 
GLP-1 receptor agonist), from a societal perspective in the 
Netherlands.
Research design and methods The IQVIA CORE Diabetes 
Model was used to project outcomes for once- weekly 
semaglutide 0.5 mg and 1 mg versus insulin glargine 
U100, once- weekly semaglutide 0.5 mg versus dulaglutide 
0.75 mg, and once- weekly semaglutide 1 mg versus 
dulaglutide 1.5 mg. Clinical data were taken from the 
SUSTAIN 4 and SUSTAIN 7 clinical trials. The analysis 
captured direct and indirect costs, mortality, and the 
impact of diabetes- related complications on quality of life.
Results Projections of outcomes suggested that once- 
weekly semaglutide 0.5 mg was associated with improved 
quality- adjusted life expectancy by 0.19 quality- adjusted 
life years (QALYs) versus insulin glargine U100 and 
0.07 QALYs versus dulaglutide 0.75 mg. Once- weekly 
semaglutide 1 mg was associated with mean increases 
in quality- adjusted life expectancy of 0.27 QALYs versus 
insulin glargine U100 and 0.13 QALYs versus dulaglutide 
1.5 mg. Improvements came at an increased cost versus 
insulin glargine U100, with incremental cost- effectiveness 
ratios from a societal perspective of €4988 and €495 
per QALY gained for once- weekly semaglutide 0.5 mg and 
1 mg, respectively, falling below Netherlands- specific 
willingness- to- pay thresholds. Improvements versus 
dulaglutide came at a reduced cost from a societal 
perspective for both doses of once- weekly semaglutide.
Conclusions Once- weekly semaglutide is cost- effective 
versus insulin glargine U100, and dominant versus 
dulaglutide 0.75 and 1.5 mg for the treatment of type 
2 diabetes, and represents a good use of healthcare 
resources in the Netherlands.
InTROduCTIOn
Choosing therapies to treat people with 
type 2 diabetes that are both effective and 
cost- effective is vital as healthcare systems 
worldwide aim to maximize health of the 
population while operating under resource 
constraints. Finite resources allocated to 
healthcare are coming under increasing 
pressure due to both growing demand and 
limited budget increases. The WHO recom-
mends the use of cost- effectiveness analysis to 
ensure that funded interventions represent 
good value for money.1 This is particularly 
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where the number of people with diabetes worldwide 
is expected to increase from 424.9 million in 2017 to 
628.6 million in 2045, with total healthcare expenditure 
due to diabetes expected to rise from US$850 billion to 
US$958 billion over the same period.2 Diabetes- related 
complications have a significant impact on the health 
status of people with diabetes, and are associated with 
significant costs, with annual costs increasing 1.7- fold, 
2- fold and 3.5- fold in people with microvascular, macro-
vascular, and both microvascular and macrovascular 
complications, respectively, compared with people with 
diabetes with no complications.3 Therefore, reducing 
the frequency of diabetes- related complications by 
controlling risk factors, including glycemia, blood 
pressure, and body weight, is key for effective and cost- 
effective therapies.4–7
Glucagon- like peptide-1 (GLP-1) receptor agonists are 
a modern therapy for type 2 diabetes with multifactorial 
benefits, reducing glycated hemoglobin (HbA1c) and 
body weight with a low risk of hypoglycemia.8 The most 
recent consensus statement released by the European 
Association for the Study of Diabetes and the American 
Diabetes Association states that GLP-1 receptor agonists 
should be considered for people with type 2 diabetes not 
achieving glycemic control targets on metformin, particu-
larly those with established cardiovascular disease (where 
evidence for a cardioprotective effect is strongest with 
liraglutide and semaglutide), with a compelling need 
to minimize hypoglycemia, or with a compelling need 
to minimize weight gain or promote weight loss.9 In the 
Netherlands, GLP-1 receptor agonists are recommended 
for patients with a body mass index (BMI) ≥35 kg/m2 
whose blood glucose values cannot be adequately regu-
lated with the combination of metformin and a sulfo-
nylurea, and those with a BMI≥30 kg/m2 who do not 
achieve blood glucose targets with optimally titrated basal 
insulin in combination with metformin (with or without 
sulfonylurea).10
Diabetes mellitus is a common chronic disease in the 
Netherlands, with over 1.1 million people affected by the 
condition.11 Estimates suggest that the total economic 
burden associated with diabetes in 2016 was €6.8 billion.12 
Of this, €2.8 billion was associated with direct healthcare 
costs, of which €1.3 billion was related to costs of compli-
cations, and €4 billion was associated with indirect costs, 
such as lost productivity, welfare payments, and indirect 
costs of complications.12 Therefore, prescribing cost- 
effective therapies for people with diabetes represents an 
opportunity to optimize the use of resources within the 
Dutch healthcare system. The present analysis assessed 
the cost- effectiveness of once- weekly semaglutide, a 
novel GLP-1 receptor agonist, from a societal perspec-
tive in the Netherlands. Once- weekly semaglutide was 
compared with once- daily insulin glargine U100 (the 
most commonly used basal insulin in the Netherlands) 




A cost- effectiveness analysis was performed by projecting 
costs and clinical outcomes over patient lifetimes 
following initiation of treatment with once- weekly sema-
glutide, daily insulin glargine U100, or dulaglutide. This 
approach aims to capture all complications, and there-
fore their impact on costs, life expectancy, and quality 
of life, as is recommended in guidelines on assessing the 
cost- effectiveness of interventions for diabetes.13 The 
analysis was performed using the IQVIA CORE Diabetes 
Model, a non- product- specific computer simulation 
model of diabetes, the capabilities and features of which 
have been published previously.14 Long- term outcomes 
projected by the model were validated against long- term 
clinical data on first publication of the model in 2004 and 
following a series of model updates in 2014.15 16
Modeled outcomes included direct medical costs, indi-
rect costs, life expectancy (measured in years), quality- 
adjusted life expectancy (measured in quality- adjusted 
life years (QALYs)), and the cumulative incidence and 
time to onset of diabetes- related complications. In cases 
where an intervention is associated with increased costs 
and greater clinical benefits, costs and effectiveness are 
combined to give an incremental cost- effectiveness ratio 
(ICER), describing the incremental cost per unit of 
effectiveness gained for the tested intervention versus 
the comparator, allowing assessment of whether an inter-
vention represents good value for money. In scenarios 
where an intervention is associated with reduced costs 
and increased clinical benefits, it is considered dominant 
versus the comparator and no calculation of an ICER 
is required. The modeling analysis took into account 
mortality following diabetes- related complications, and 
background mortality based on Netherlands- specific life 
tables.17 Future clinical benefits were discounted at 1.5% 
per annum and future costs were discounted at 4% per 
annum, in line with guidelines for economic evaluation 
in the Netherlands.18
Clinical data
Clinical data for the comparison of once- weekly sema-
glutide with daily insulin glargine U100 were taken from 
the SUSTAIN 4 clinical trial, while the SUSTAIN 7 clin-
ical trial provided data for the comparison with dula-
glutide.19 20 SUSTAIN 4 was a 30- week open- label trial 
comparing once- weekly semaglutide 0.5 mg and 1 mg 
with daily insulin glargine U100 in people with type 2 
diabetes with an HbA1c of 7.0%–10.0% on metformin 
either alone or in combination with a sulfonylurea. 
SUSTAIN 7 was a 40- week, randomized, open- label trial 
comparing once- weekly semaglutide 0.5 mg and 1 mg 
with once- weekly dulaglutide 0.75 and 1.5 mg in people 
with type 2 diabetes with an HbA1c of 7.0%–10.5% while 
on metformin monotherapy. Data were obtained from 
prespecified endpoints wherever possible, but in order 
to fulfill all of the data requirements for an analysis using 
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Table 1 Baseline cohort characteristics
SUSTAIN 4 SUSTAIN 7
Age (years) 56 (10) 56 (11)
Duration of diabetes (years) 9 (6)* 7 (6)*
Percentage male (%) 53 55
HbA1c (%) 8.3 (0.9) 8.2 (0.9)
Systolic blood pressure (mm Hg) 132 (15) 133 (14)
Total cholesterol (mg/dL) 179 (42) 181 (43)
HDL cholesterol (mg/dL) 46 (12) 45 (11)
LDL cholesterol (mg/dL) 97 (35) 102 (37)
Triglycerides (mg/dL) 190 (124) 181 (109)
BMI (kg/m2) 33.0 (6.5) 33.5 (6.8)
Values are means (SD).
*Rounded as the IQVIA CORE Diabetes Model only accepts 
integer values for duration of diabetes.
BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high- 
density lipoprotein;LDL, low- density lipoprotein.
Table 2 Treatment effects and adverse event rates




















−5 (0.7)* −5 (0.7)* −2 (0.7) −2 (0.8) −2 (0.8) −5 (0.8) −3 (0.8)
Total cholesterol 
(mg/dL)
−9 (1.6)* −9 (1.6)* −2 (1.6) −7 (1.7) −6 (1.8) −5 (1.8) −3 (1.8)
HDL cholesterol 
(mg/dL)
−1 (0.4) 0 (0.4)* −1 (0.3) 0 (0.3) 0 (0.4) 1 (0.4) 1 (0.4)
LDL cholesterol 
(mg/dL)
−4 (1.3)* −5 (1.3)* 1 (1.4) −3 (1.5) −3 (1.5) 0 (1.6) 1 (1.5)
Triglycerides 
(mg/dL)
−18 (3.2) −22 (3.1)* −12 (3.2) −14 (3.1) −14 (3.1) −22 (2.9) −16 (3.0)
BMI (kg/m2) −1.2 (0.1)* −1.9 (0.1)* 0.4 (0.1) −1.6 (0.1)* −0.8 (0.1) −2.3 (0.1)* −1.1 (0.1)
Non- severe 
hypoglycemia 
(events per 100 
patient- years)
12 13 27 1 1 3 1
Severe 
hypoglycemia 
(events per 100 
patient- years)
2 5 2 0 0 0 1
Proportion of 
non- severe 
events that are 
nocturnal
0.18 0.11 0.11 0.00 0.00 0.00 0.00
Proportion 
of severe 
events that are 
nocturnal
0.00 0.00 0.20 0.00 0.00 0.00 0.00
*Statistically significant difference at 95% confidence level. Values are means (SE).
BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high- density lipoprotein; LDL, low- density lipoprotein.
data extractions from the trial data were required (serum 
lipids and hypoglycemic events, to ensure that definitions 
met those used in the IQVIA CORE Diabetes Model).
The cost- effectiveness analysis used the baseline cohorts 
from SUSTAIN 4 and 7 (table 1) and applied the changes 
from baseline and adverse event rates from the end of the 
respective trials (table 2). The clinical benefits, adverse 
events and costs associated with rescue therapy were not 
captured in the analysis. In line with the trial protocols, 
both doses of once- weekly semaglutide were compared 
with insulin glargine, once- weekly semaglutide 0.5 mg 
was compared with dulaglutide 0.75 mg, and once- weekly 
semaglutide 1 mg was compared with dulaglutide 1.5 mg. 
Across all comparisons, once- weekly semaglutide was 
associated with statistically significant improvements in 
HbA1c and BMI versus the comparator therapy.
Patients were assumed to receive once- weekly semaglu-
tide, dulaglutide or insulin glargine U100 29.2 IU (the 
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the analysis, based on a review of treatments for type 2 
diabetes conducted in 2017, which concluded that the 
mean duration of GLP-1 receptor agonist treatment was 
29.4 months, as patients may switch to more advanced 
therapy due to the progressive nature of the disease.21 
This was rounded up to 3 years, as treatment switching 
is only possible at the end of a given year in the IQVIA 
CORE Diabetes Model. After 3 years, once- weekly sema-
glutide or dulaglutide treatment was discontinued and 
patients received 40 IU insulin glargine U100 per day. 
Patients in the insulin glargine arm continued this 
therapy, with the dose increased from 29.2 to 40 IU. This 
resulted in equal treatment costs in all arms following 
treatment intensification at 3 years. This approach is in 
line with previous long- term cost- effectiveness analyses of 
GLP-1 receptor agonists submitted to the Scottish Medi-
cines Consortium and the National Institute for Health 
and Care Excellence, and published in peer- reviewed 
journals.22–27 Differences in HbA1c, BMI and hypogly-
cemic event rates between the study arms were assumed 
to persist for the first 3 years of the analysis, as patients 
received different therapies and accrued different treat-
ment costs in this period. This resulted in a balanced 
cost- effectiveness analysis, with differences in these key 
inputs maintained only while there were differences in 
treatment costs.
Costs
The analysis evaluated cost- effectiveness from a societal 
perspective, capturing both direct and indirect costs in 
2017 euros (EUR), in line with guidance on the evalu-
ation of new health technologies in the Netherlands.18 
Direct costs included costs of diabetes medications, 
costs of consumables (such as needles for injection of 
insulin and self- monitoring of blood glucose supplies), 
and costs associated with diabetes- related complications. 
Indirect costs were assessed in terms of lost workplace 
productivity due to diabetes- related complications and 
mortality.
Pharmacy and consumables costs were based on list 
prices published for the Netherlands (online supple-
mentary table 1).28 Diabetes medication resource use 
was taken from the SUSTAIN 4 and 7 trials, and used 
to calculate annual treatment costs. A mean daily dose 
of 29.2 IU insulin glargine U100 was used to calculate 
annual treatment costs over the first 3 years of the anal-
ysis in the insulin glargine arm, based on the end of 
trial dose in SUSTAIN 4 (no increase in insulin dose 
over the 3 years was modeled). After 3 years, a dose of 
40 IU insulin glargine U100 was used to calculate treat-
ment costs in all treatment arms. A targeted literature 
review was performed in 2018 to collect costs associated 
with diabetes- related complications in the Netherlands 
(online supplementary table 2). Indirect costs were based 
on days off work estimates following diabetes- related 
complications, and mean salary and retirement age in 
the Netherlands.29
Quality of life utilities
As diabetes progresses, patients develop complications 
that influence their overall health- related quality of life. 
It was therefore important to evaluate utility levels asso-
ciated with each of the complications modeled. Utilities 
relating to quality of life were taken from a 2014 review 
by Beaudet et al with the exception of hypoglycemic event 
disutilities, which were sourced from a 2013 publication 
by Evans et al (published after the literature searches by 
Beaudet et al had been conducted).30 31
sensitivity analyses
Projection of outcomes over patient lifetimes based on 
short- term clinical trial data is associated with uncertainty, 
and therefore sensitivity analyses were conducted to eval-
uate the robustness of the results and identify key drivers 
of modeled outcomes. Sensitivity analyses included vari-
ation of the time horizon of the analysis, discount rates 
applied, treatment effects applied, HbA1c progression 
approaches, timing of treatment switching, costs of 
complications, risk equations used to predict cardiovas-
cular events, and utilities applied. In addition, probabi-
listic sensitivity analysis (PSA) was performed using the 
predefined function in the IQVIA CORE Diabetes Model.
subgroup analyses
The base case analyses were based on data from all 
patients enrolled in the SUSTAIN 4 and 7 clinical trials, 
in order to use the most robust data sources to inform the 
analyses. However, in the Netherlands, the reimburse-
ment of GLP-1 receptor agonists is currently limited to 
people with type 2 diabetes with a BMI≥35 kg/m2 whose 
blood glucose values cannot be adequately regulated 
with the combination of metformin and a sulfonylurea, 
and those with a BMI ≥30 kg/m2 who do not achieve 
blood glucose targets with optimally titrated basal insulin 
in combination with metformin (with or without sulfony-
lurea).10 Therefore, subgroup analyses based on patients 
with BMI ≥30 and ≥35 kg/m2 at baseline in the SUSTAIN 
4 and 7 trials were prepared.
ResulTs
Once-weekly semaglutide versus once-daily insulin glargine
Base case analyses
Both doses of once- weekly semaglutide were associated 
with improved discounted life expectancy and quality- 
adjusted life expectancy versus once- daily insulin glargine 
U100 (table 3). Once- weekly semaglutide 0.5 mg was asso-
ciated with improvements in life expectancy and quality- 
adjusted life expectancy of 0.20 years and 0.19 QALYs per 
patient, respectively, and benefits were slightly greater 
with once- weekly semaglutide 1 mg at 0.28 years and 0.27 
QALYs per patient, respectively. A reduced incidence of 
diabetes- related complications and an increased time to 
their onset led to improved duration and quality of life 
with once- weekly semaglutide 0.5 mg and 1 mg compared 
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Table 3 Base case results
Semaglutide 0.5 mg Insulin glargine U100 Difference
Discounted life expectancy (years) 18.35 (0.27) 18.15 (0.29) +0.20
Discounted quality- adjusted life 
expectancy (QALYs)
12.05 (0.18) 11.85 (0.19) +0.19
Discounted direct costs (€) 26 780 (1054) 24 627 (1136) +2152
Discounted combined costs (€) 46 860 (1903) 45 911 (1967) +949
ICER based on direct costs €11 310 per QALY gained
ICER based on combined costs €4988 per QALY gained
 Semaglutide 1 mg Insulin glargine U100 Difference
Discounted life expectancy (years) 18.44 (0.27) 18.15 (0.29) +0.28
Discounted quality- adjusted life expectancy 
(QALYs)
12.12 (0.18) 11.85 (0.19) +0.27
Discounted direct costs (€) 26 654 (1112) 24 627 (1136) +2027
Discounted combined costs (€) 46 044 (1934) 45 911 (1967) +133
ICER based on direct costs €7515 per QALY gained
ICER based on combined costs €495 per QALY gained
 
Once- weekly semaglutide 
0.5 mg Dulaglutide 0.75 mg Difference
Discounted life expectancy (years) 17.56 (0.29) 17.51 (0.27) +0.06
Discounted quality- adjusted life expectancy 
(QALYs)
11.53 (0.19) 11.46 (0.18) +0.07
Discounted direct costs (€) 26 133 (1070) 25 819 (1124) +314
Discounted combined costs (€) 46 160 (1935) 46 606 (2013) −446
ICER based on direct costs €4671 per QALY gained
ICER based on combined costs Once- weekly semaglutide 0.5 mg dominant
 Semaglutide 1 mg Dulaglutide 1.5 mg Difference
Discounted life expectancy (years) 17.69 (0.27) 17.55 (0.28) +0.14
Discounted quality- adjusted life expectancy 
(QALYs)
11.63 (0.18) 11.50 (0.18) +0.13
Discounted direct costs (€) 25 945 (1025) 25 565 (1070) +381
Discounted combined costs (€) 45 365 (1880) 45 820 (1922) −455
ICER based on direct costs €2861 per QALY gained
ICER based on combined costs Once- weekly semaglutide 1 mg dominant
Values are means (SD).
€, 2017 euros (EUR); ICER, incremental cost- effectiveness ratio; QALY, quality- adjusted life year.
Both doses of once- weekly semaglutide were associ-
ated with increased direct costs compared with insulin 
glargine U100. This resulted from higher pharmacy costs 
during the first 3 years of the analysis (figure 1), as once- 
weekly semaglutide 0.5 mg and 1 mg were associated with 
higher treatment costs than 29.2 IU insulin glargine U100 
once daily (based on the end of study dose). Reduced 
costs of treating diabetes- related complications partially 
offset higher pharmacy costs, with the largest cost savings 
resulting from avoided cardiovascular complications 
(mean cost savings of €283 and €425 per patient with 
once- weekly semaglutide 0.5 mg and 1 mg, respectively). 
Both doses of once- weekly semaglutide were associated 
with fewer diabetes- related complications, leading to 
less lost workplace productivity and mean indirect cost 
savings of €1203 with once- weekly semaglutide 0.5 mg 
and €1893 with once- weekly semaglutide 1 mg. When 
direct and indirect costs were combined, once- weekly 
semaglutide 0.5 mg was associated with increased costs of 
€949 per patient and once- weekly semaglutide 1 mg was 
associated with increased costs of €133 per patient versus 
insulin glargine U100.
Projections over patient lifetimes suggested that once- 
weekly semaglutide 0.5 mg was associated with ICERs of 
€11 310 per QALY gained based on direct costs, and 
€4988 per QALY gained based on combined costs versus 
insulin glargine U100. Once- weekly semaglutide 1 mg 
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Figure 1 Costs over patient lifetimes in the base case analyses.
Table 4 Subgroup analysis results
Base case (all patients) BMI≥30 kg/m2 BMI≥35 kg/m2
SUSTAIN 4: Semaglutide 0.5 mg versus insulin glargine U100
ICER based on direct costs €11 310 per QALY gained €11 184 per QALY gained €13 205 per QALY gained
ICER based on combined costs €4988 per QALY gained €4541 per QALY gained €7463 per QALY gained
SUSTAIN 4: Semaglutide 1 mg versus insulin glargine U100
ICER based on direct costs €7515 per QALY gained €6384 per QALY gained €5564 per QALY gained
ICER based on combined costs €495 per QALY gained Semaglutide dominant Semaglutide dominant
SUSTAIN 7: Semaglutide 0.5 mg versus dulaglutide 0.75 mg
ICER based on direct costs €4671 per QALY gained €3917 per QALY gained €2149 per QALY gained
ICER based on combined costs Semaglutide dominant Semaglutide dominant Semaglutide dominant
SUSTAIN 7: Semaglutide 1 mg versus dulaglutide 1.5 mg
ICER based on direct costs €2861 per QALY gained €2855 per QALY gained €3392 per QALY gained
ICER based on combined costs Semaglutide dominant Semaglutide dominant Semaglutide dominant
€, 2017 euros (EUR); BMI, body mass index; ICER, incremental cost- effectiveness ratio; QALY, quality- adjusted life year.
costs of €7515 per QALY gained and €495 per QALY 
gained versus insulin glargine U100, respectively.
Sensitivity analyses
The conclusions of the base case analyses were confirmed 
by extensive sensitivity analyses. Full results of the sensi-
tivity analyses comparing once- weekly semaglutide 0.5 
mg and 1 mg with insulin glargine U100 can be found 
in the online supplementary tables 3 and 4. Cost- 
effectiveness scatterplots and cost- effectiveness accept-
ability curves generated in the PSA are also available in 
the online supplementary figures 1 and 2.
Subgroup analyses
Projection of long- term clinical outcomes in people 
with diabetes with BMI ≥30 and ≥35 kg/m2 showed that 
results were consistent with the base case analysis in all 
patients (table 4). Results were similar in all three anal-
yses comparing once- weekly semaglutide 0.5 mg with 
insulin glargine U100, with comparable differences in 
life expectancy, quality- adjusted life expectancy, direct 
costs, and indirect costs. The 1 mg dose of once- weekly 
semaglutide was associated with greater clinical benefits 
over insulin glargine U100 in people with a higher BMI 
at baseline. ICERs based on direct costs fell to €6384 per 
QALY gained in people with a BMI≥30 kg/m2 and €5564 
per QALY gained in people with a BMI≥35 kg/m2. When 
combined costs were taken into account, once- weekly 
semaglutide 1 mg was found to be dominant versus insulin 
glargine U100 in people with BMI ≥30 and ≥35 kg/m2.
Once-weekly semaglutide versus dulaglutide
Base case analyses
Projections of outcomes over patient lifetimes suggested 
that once- weekly semaglutide 0.5 mg was associated with 
improved discounted life expectancy and quality- adjusted 
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respectively, versus dulaglutide 0.75 mg (table 3). Simi-
larly, once- weekly semaglutide 1 mg was associated with 
mean increases in life expectancy of 0.14 years and quality- 
adjusted life expectancy of 0.13 QALYs versus dulaglutide 
1.5 mg (table 3). In both cases, improvements in clinical 
outcomes were driven by a reduced cumulative incidence 
and delayed time to onset of complications over the long 
term.
When direct costs were considered, both 0.5 mg and 
1 mg doses of once- weekly semaglutide were associated 
with increased treatment costs compared with dulaglu-
tide 0.75 and 1.5 mg, due to higher pharmacy costs over 
the first 3 years of the analysis (figure 1). However, this 
was partially offset by cost savings resulting from avoided 
complications, most notably ophthalmic complications 
with once- weekly semaglutide 0.5 mg and cardiovascular 
complications with once- weekly semaglutide 1 mg. Once- 
weekly semaglutide 0.5 mg and 1 mg were associated with 
mean indirect cost savings of €760 and €835 per patient, 
respectively, resulting from reduced lost productivity due 
to fewer diabetes- related complications and reduced 
mortality. ICERs based on direct costs were €4671 per 
QALY gained for once- weekly semaglutide 0.5 mg versus 
dulaglutide 0.75 mg, and €2861 per QALY gained for 
once- weekly semaglutide 1 mg versus dulaglutide 1.5 mg. 
When combined (both direct and indirect) costs were 
included, both doses of once- weekly semaglutide were 
found to be dominant (associated with improved clinical 
outcomes and cost savings) versus the comparator doses 
of dulaglutide.
Sensitivity analyses
Extensive sensitivity analyses confirmed the conclusions 
of the base case analyses. Full results of the sensitivity 
analyses comparing once- weekly semaglutide 0.5 mg 
with dulaglutide 0.75 mg, and once- weekly semaglutide 
1 mg with dulaglutide 1.5 mg can be found in the online 
supplementary tables 5 and 6. Cost- effectiveness scatter-
plots and cost- effectiveness acceptability curves generated 
in the PSA are also available in the online supplementary 
figures 3–6.
Subgroup analyses
Evaluation of outcomes in people with diabetes with 
BMI ≥30 and ≥35 kg/m2 found that the conclusions did 
not differ from the base case analyses conducted in all 
patients (table 4). Differences in life expectancy, quality- 
adjusted life expectancy, direct costs and indirect costs 
were similar to the base case analyses. Once- weekly sema-
glutide 0.5 mg remained dominant versus dulaglutide 
0.75 mg and once- weekly semaglutide 1 mg was found to 
be dominant versus dulaglutide 1.5 mg in both subgroups.
dIsCussIOn
Projections over patient lifetimes based on two randomized 
controlled trials suggested that once- weekly semaglutide 
would improve clinical outcomes compared with insulin 
glargine U100 and dulaglutide for treatment of people 
with type 2 diabetes. These improvements were achieved at 
an increased cost from a societal perspective versus insulin 
glargine U100 but at a reduced cost from a societal perspec-
tive versus dulaglutide. Decision- making around reim-
bursement of interventions which improve outcomes and 
reduce costs is straightforward, but decision- making when 
interventions improve outcomes and increase costs is more 
nuanced, requiring assessment of whether the additional 
benefits are worth the additional costs. These value- for- 
money assessments can be made by comparing the ICER 
generated in the analysis with a willingness- to- pay threshold, 
representing the maximum amount an individual or society 
is prepared to pay in order to gain 1 QALY. A number of 
willingness- to- pay thresholds have been suggested for the 
Netherlands, with €20 000 per QALY gained often quoted, 
and discussion of a willingness- to- pay threshold of €80 
000 per QALY gained for very severe diseases.32 A study 
attempting to identify the willingness- to- pay threshold of 
individuals in the Netherlands found that the willingness- 
to- pay threshold ranged from €12 900 per QALY gained 
to €24 500 per QALY gained, depending on the measure 
used to assess quality of life.33 All base case ICERs versus 
insulin glargine U100 and dulaglutide in the present anal-
ysis fell below the lowest willingness- to- pay threshold, even 
with the most stringent definition of value for money in 
the Netherlands. Use of once- weekly semaglutide for treat-
ment of patients with type 2 diabetes in the Netherlands is, 
therefore, likely to be a good use of healthcare resources.
At present, reimbursement of GLP-1 receptor agonists 
in the Netherlands is limited to people with type 2 
diabetes with a BMI≥35 kg/m2 whose blood glucose 
values cannot be adequately regulated with the combi-
nation of metformin and a sulfonylurea, and those with 
a BMI≥30 kg/m2 who do not achieve blood glucose 
targets with optimally titrated basal insulin in combina-
tion with metformin (with or without a sulfonylurea).10 
The present analysis assessed outcomes in all patients in 
the base case analyses, in line with the inclusion criteria 
of the SUSTAIN 4 and 7 clinical trials. In the SUSTAIN 
4 and 7 trials, mean BMI was 33.01 and 33.50 kg/m2, 
respectively, and therefore a number of patients would 
meet the reimbursement criteria for a GLP-1 receptor 
agonist, but others would not. To investigate the impact 
of baseline BMI on cost- effectiveness, the present anal-
ysis included subgroup analyses in patients with BMI ≥30 
and ≥35 kg/m2. These analyses showed that once- weekly 
semaglutide is likely to be cost- effective in all patient 
groups analyzed and therefore is likely to be a good use 
of healthcare resources in patients with a BMI≥30 kg/m2.
Cost- effectiveness analyses in other country settings 
support the results of the present analysis. An evaluation 
based on SUSTAIN 7 for the UK found that both doses 
of once- weekly semaglutide were dominant versus dula-
glutide from a healthcare payer perspective.27 Similarly, 
in an analysis prepared for the Canadian setting (using 
a different health economic model), once- weekly sema-
glutide 0.5 mg was dominant versus dulaglutide 0.75 mg 
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dulaglutide 1.5 mg.34 In Estonia, a cost- effectiveness 
analysis has suggested that once- weekly semaglutide 
is cost- effective versus liraglutide, improving clinical 
outcomes with only a small increase in costs.35 An anal-
ysis for Denmark found that once- weekly semaglutide 
0.5 mg and 1 mg were either cost- effective or dominant 
versus a range of GLP-1 receptor agonists.36 Numerous 
factors may influence the cost- effectiveness of interven-
tions in different countries, including pharmacy costs, 
costs of treating complications, and healthcare funding 
models, but once- weekly semaglutide appears to be 
consistently cost- effective in a range of countries. To 
date, no other studies have assessed the cost- effectiveness 
of once- weekly semaglutide versus insulin glargine U100 
based on SUSTAIN 4.
There is increasing interest in the impact of GLP-1 
receptor agonists on cardiovascular risk. Efficacy appears 
to vary between GLP-1 receptor agonists, with once- 
weekly semaglutide, liraglutide, dulaglutide and albiglu-
tide shown to reduce the risk of cardiovascular events, 
but lixisenatide and exenatide extended release shown 
to have no impact compared with placebo.37–42 It was 
not possible to take into account the impact of interven-
tions on cardiovascular risk in the present analysis, as risk 
equations based on the cardiovascular outcome studies 
have not yet been integrated into cost- effectiveness 
models. Exclusion of the direct cardioprotective effect 
observed with semaglutide, particularly in the compar-
ison with insulin glargine U100 which has been shown 
to have no cardioprotective effect, is a conservative 
approach, with a modeling study based on the SUSTAIN 
6 trial showing that conventional risk equations underes-
timate the reduced incidence of stroke with once- weekly 
semaglutide.43 The cardiovascular outcome trials in type 
2 diabetes have been conducted in patients with varying 
characteristics, most notably with differing cardiovas-
cular risk profiles at baseline. Studies in homogeneous 
populations are required to assess the relative impact of 
different GLP-1 receptor agonists on cardiovascular risk, 
and subsequently capture any differences in risk equa-
tions for use in health economic analyses. Nevertheless, 
the cardiovascular benefits for semaglutide reported in 
the SUSTAIN 6 study may increase the cost- effectiveness 
of once- weekly semaglutide, particularly in comparison 
with insulin glargine U100.
As with many health economic analyses of interven-
tions for type 2 diabetes, a limitation of the present 
analysis was the use of short- term data to project 
long- term outcomes. However, modeled projections 
represent the best available option for healthcare 
decision- making in the absence of long- term clinical 
trial data. Projection of outcomes over patient lifetimes 
is recommended in guidelines for assessing the cost- 
effectiveness of diabetes interventions, and the present 
analysis attempted to mitigate the inherent uncertainty 
through use of a published and extensively validated 
model and through preparation of extensive sensitivity 
analyses.13–16
A further limitation of the analysis was that adherence 
and persistence were not captured. There are currently 
no data to inform rates of adherence and persistence 
with once- weekly semaglutide, dulaglutide and insulin 
glargine U100 over the long term. There are also no data 
to inform how risk factors, such as HbA1c and BMI would 
be affected by non- adherence and non- persistence. Simi-
larly, switching between doses of GLP-1 receptor agonists 
and titration of the insulin glargine U100 was not 
captured, as there are no data available to inform rates of 
switching or titration, or the subsequent changes in risk 
factors. Further studies in real- world clinical practice are 
required to examine adherence, persistence and changes 
in dose, and how these affect risk factors for diabetes- 
related complications, with these data then included in 
further evaluations of cost- effectiveness.
COnClusIOns
Projections suggest that once- weekly semaglutide 0.5 mg 
and 1 mg are likely to improve clinical outcomes for 
patients with type 2 diabetes compared with insulin 
glargine and dulaglutide. Compared with insulin glargine 
U100, improvements in clinical outcomes came at an 
increased cost, but once- weekly semaglutide was consid-
ered cost- effective, even at the lowest willingness- to- pay 
threshold identified in the Netherlands. Improvements 
came at a reduced cost from a societal perspective versus 
dulaglutide, and therefore once- weekly semaglutide was 
considered dominant. Use of once- weekly semaglutide 
for treatment of patients with type 2 diabetes is, there-
fore, likely to be a good use of healthcare resources in 
the Netherlands.
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